Gamma-Secretase inhibitors as novel pharmacological agents to target stroke-induced brain injury

γ-分泌酶抑制剂作为针对中风引起的脑损伤的新型药物

• 批准号: nhmrc : 1008048
• 负责人: A/Pr Thiruma Arumugam
• 金额: $ 29.44万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/gamma-secretase-inhibitors-brain-injury/109271
• 关键词: Gamma; Secretase; inhibitors; novel; pharmacological

Stroke is the world�s 2nd leading cause of death. In Australia, stroke is the leading cause of serious, long-term disability. Alarmingly, there is a looming stroke epidemic in Australia. There is an urgent need for novel therapies capable of reducing mortality and long-term disability in victims of stroke. We have recently identified gamma-secretase inhibitors (GSIs) as a potent stroke therapy. This project will investigate how GSIs protect against ischaemic stroke at the molecular level.

中风是世界上第二大死亡原因。在澳大利亚，中风是导致严重、长期残疾的主要原因。令人担忧的是，澳大利亚正在出现中风流行病。迫切需要能够降低中风患者死亡率和长期残疾的新疗法。我们最近发现γ-分泌酶抑制剂（GSI）作为一种有效的中风治疗。该项目将研究GSI如何在分子水平上预防缺血性卒中。